0.68
-0.0301(-4.24%)
Currency In USD
| Previous Close | 0.71 |
| Open | 0.71 |
| Day High | 0.72 |
| Day Low | 0.68 |
| 52-Week High | 3.87 |
| 52-Week Low | 0.54 |
| Volume | 81,456 |
| Average Volume | 280,091 |
| Market Cap | 12.68M |
| PE | -1.05 |
| EPS | -0.65 |
| Moving Average 50 Days | 0.95 |
| Moving Average 200 Days | 1.14 |
| Change | -0.03 |
If you invested $1000 in Nexalin Technology, Inc. (NXL) since IPO date, it would be worth $302.22 as of January 14, 2026 at a share price of $0.68. Whereas If you bought $1000 worth of Nexalin Technology, Inc. (NXL) shares 3 years ago, it would be worth $735.14 as of January 14, 2026 at a share price of $0.68.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
GlobeNewswire Inc.
Dec 03, 2025 1:00 PM GMT
FDA feedback provides clear framework for Nexalin’s planned U.S. Pilot Study and supports a potential De Novo pathway for the Gen-2 SYNC™ device in Alzheimer’s diseaseHOUSTON, TX, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq:
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4
GlobeNewswire Inc.
Dec 02, 2025 1:00 PM GMT
HOUSTON, TX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL) is pleased to invite investors to a webinar on December 4, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies,
Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity
GlobeNewswire Inc.
Nov 18, 2025 2:00 PM GMT
Peer-reviewed case report published in The American Journal on Addictions highlights significant clinical improvement and sustained abstinence following Nexalin’s non-invasive therapyHOUSTON, TX, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology